FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of growth factor-specific muteins (GDF15) and conjugates thereof, and can be used in medicine.
EFFECT: obtained muteins of GDF15 have higher solubility compared to natural GDF15 and are used to prepare pharmaceutical compositions for effective treatment of obesity and hyperglycemia.
27 cl, 34 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED POLYPEPTIDE WITH ANTICANCER ACTIVITY | 2016 |
|
RU2727165C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| MUTEINS OF TEAR LIPOCALIN, POSSESSING AFFINITY TO HUMAN C-MET RECEPTOR TYROSINE KINASE AND METHODS OF OBTAINING THEM | 2009 |
|
RU2515063C9 |
| THERAPEUTIC USE OF VEGF-C AND CCBE1 | 2014 |
|
RU2691104C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| ANTIGEN MOLECULAR MASSIFS | 2003 |
|
RU2324704C2 |
| FUSION POLYPEPTIDE INCLUDING Fc REGION OF IMMUNOGLOBULIN AND GDF15 | 2020 |
|
RU2797520C2 |
